Deals

What’s Next for Alcon Spin-off

By Rich Kirkner | July 2, 2018

As Novartis unveiled plans to spin off its Alcon eye care unit, the Swiss healthcare giant named Alcon CEO Mike Ball chairman-designate to guide the…

OIS Index Breaks 1,000 as Rally in Ophthalmic Stocks Rolls On

By Michael Lachman | June 6, 2018

The OIS Index returned to four-digit territory in May, surpassing 1,000 for the first time since the index was launched in October 2016. The OIS…

Ophthalmic Stocks’ Rally Rolls Through April

By Michael Lachman | May 2, 2018

The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over…

15 Things We Learned at OIS@ASCRS

By Rich Kirkner | April 20, 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…

Lurker Describes Next Steps for EyePoint

By Rich Kirkner | April 11, 2018

Within a week Nancy Lurker went from president and CEO of what had been known as an R&D company to the same title at a…

41 Things On Tap at OIS@ASCRS

By Rich Kirkner | April 4, 2018

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…

OIS Index Outperforms Market in Another Volatile Month

By Michael Lachman | April 4, 2018

The OIS Index gained 4.4% in March, far outperforming its key benchmarks during another volatile month for the markets. The NASDAQ Biotechnology Index declined by…

OIS Index Follows Market Downward During a Rocky February

By Michael Lachman | March 2, 2018

The OIS Index declined by 4.2% in February, tracking stock market benchmarks during a volatile month. The NASDAQ Biotechnology Index suffered a slightly larger decline…

OIS Index Delivers Small Gain, But Lags Benchmarks in January

By Michael Lachman | February 7, 2018

In January, the OIS Index scratched out a small gain, but underperformed its relevant benchmarks. The OIS Index gained 0.3%, compared with gains of 7%…

With Early Rhopressa ‘Present,’ Aerie Plots Next Steps

By Steve Lenier | January 17, 2018

Aerie Pharmaceuticals’ CEO and chairman Vicente Anido Jr., PhD, says the company got “an early Christmas present” when the Food and Drug Administration approved Rhopressa…